RU2003134180A - Комбинированная терапия, использующая антитела к egfr и антигормональные средства - Google Patents
Комбинированная терапия, использующая антитела к egfr и антигормональные средства Download PDFInfo
- Publication number
- RU2003134180A RU2003134180A RU2003134180/15A RU2003134180A RU2003134180A RU 2003134180 A RU2003134180 A RU 2003134180A RU 2003134180/15 A RU2003134180/15 A RU 2003134180/15A RU 2003134180 A RU2003134180 A RU 2003134180A RU 2003134180 A RU2003134180 A RU 2003134180A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- antibody
- composition according
- agent
- pharmaceutical
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 title 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 title 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 239000013059 antihormonal agent Substances 0.000 claims 6
- 229940127089 cytotoxic agent Drugs 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 102000007451 Steroid Receptors Human genes 0.000 claims 3
- 108010085012 Steroid Receptors Proteins 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 239000002254 cytotoxic agent Substances 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 108060006698 EGF receptor Proteins 0.000 claims 1
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000002474 gonadorelin antagonist Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (20)
1. Фармацевтическая композиция, содержащая в терапевтически эффективном количестве по крайней мере (i) одно антитело к EGFR или его иммунотерапевтически эффективный фрагмент и (ii) одно антигормональное средство необязательно совместно с фармацевтически приемлемым носителем, наполнителем или растворителем.
2. Фармацевтическая композиция по п.1, в которой указанное антитело к EGFR или указанный его иммунотерапевтически эффективный фрагмент представляет собой мышиный, химерный или гуманизированный Mab 425 (h425) или химерный Mab 225 (с225) ингибитор/антагонист.
3. Фармацевтическая композиция по п.1, в которой указанное антигормональное средство представляет собой ингибитор семейства ядерных рецепторов гормонов.
4. Фармацевтическая композиция по п.3, в которой указанное антигормональное средство представляет собой ингибитор/антагонист стероидного рецептора.
5. Фармацевтическая композиция по любому из пп.1-4, которая дополнительно содержит антиангиогенное средство.
6. Фармацевтическая композиция по любому из пп.1-4, которая также содержит цитотоксическое и/или химиотерапевтическое средство.
7. Фармацевтическая композиция по любому из пп.1-4, которая дополнительно содержит также антитело к HER2 или его иммунотерапевтически эффективный фрагмент.
8. Фармацевтическая композиция, содержащая антитело, имеющее анти-EGFR активность и активность против ядерного рецептора гормона необязательно совместно с фармацевтически приемлемым носителем, наполнителем или растворителем.
9. Фармацевтическая композиция по п.8, в которой указанное антитело представляет собой биспецифическое антитело.
10. Фармацевтический набор, который включает упаковку, содержащую по крайней мере (i) одно антитело к EGFR или его иммунотерапевтическиэффективный фрагмент, и (ii) одно антигормональное средство, и необязательно (iii) цитотоксическое и/или химиотерапевтическое средство.
11. Фармацевтический набор по п.10, содержащий (i) моноклональное антитело h425 и (ii) антагонист стероидного рецептора.
12. Фармацевтический набор по п.11, содержащий (i) моноклональное антитело h425 и (ii) LHRH антагонист.
13. Фармацевтический набор по любому из пп.10-12, в котором указанные фармацевтически активные средства находятся в отдельных контейнерах в указанной упаковке.
14. Применение фармацевтической композиции по любому из пп.1-9 или фармацевтического набора по любому из пп.10-13 для приготовления лекарственного средства или композиции лекарственных средств для лечения опухолей и метастазов опухолей.
15. Применение по п.14 для лечения рака молочной железы.
16. Применение по п.14 для лечения рака предстательной железы.
17. Применение по п.15 или 16 для лечение стероиднезависимого рака молочной железы и рака предстательной железы.
18. Способ лечения опухолей или метастазов опухолей у особи, который предусматривает введение указанной особи одновременно или последовательно терапевтически эффективного количества (i) антитела к EGFR и (ii) антигормонального средства.
19. Способ по п.18, при котором указанное антитело к EGFR представляет собой моноклональное антитело h425 или с225 и указанное антигормональное средство представляет собой антагонист стероидного рецептора.
20. Способ по п.18 или 19, который включает дополнительное введение указанной особи терапевтически эффективного количества цитотоксического, и/или химиотерапевтического средства, или антиангиогенного средства, или другого антитела к рецептору ErbB.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01111049.1 | 2001-05-08 | ||
| EP01111049 | 2001-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2003134180A true RU2003134180A (ru) | 2005-02-10 |
Family
ID=8177348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003134180/15A RU2003134180A (ru) | 2001-05-08 | 2002-04-22 | Комбинированная терапия, использующая антитела к egfr и антигормональные средства |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20040131611A1 (ru) |
| EP (1) | EP1385546A1 (ru) |
| JP (1) | JP2004528368A (ru) |
| KR (1) | KR20040029975A (ru) |
| CN (1) | CN1507355A (ru) |
| AU (1) | AU2002315306B2 (ru) |
| BR (1) | BR0209147A (ru) |
| CA (1) | CA2449166A1 (ru) |
| CZ (1) | CZ20033226A3 (ru) |
| HU (1) | HUP0303976A3 (ru) |
| MX (1) | MXPA03010121A (ru) |
| PL (1) | PL363322A1 (ru) |
| RU (1) | RU2003134180A (ru) |
| SK (1) | SK14632003A3 (ru) |
| WO (1) | WO2002089842A1 (ru) |
| ZA (1) | ZA200309437B (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2416399C2 (ru) * | 2005-06-29 | 2011-04-20 | Хилл'С Пет Ньютришн, Инк. | Способы и композиции для профилактики и лечения воспалительного заболевания |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1392359E (pt) | 2001-05-11 | 2010-01-27 | Ludwig Inst For Cancer Res Ltd | Proteínas de ligação específica e suas utilizações |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| DE60237282D1 (de) * | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
| US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| DK1517921T3 (da) * | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| CA2511910A1 (en) * | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| AU2004226162A1 (en) * | 2003-04-04 | 2004-10-14 | Universite De Lausanne | Peptabody for cancer treatment |
| KR100872204B1 (ko) * | 2003-10-15 | 2008-12-09 | 오에스아이 파마슈티컬스, 인코포레이티드 | 이미다조피라진 티로신 키나제 억제제 |
| DE602005014964D1 (de) | 2004-04-02 | 2009-07-30 | Osi Pharm Inc | Mit einem 6,6-bicyclischen ring substituierte heterobicyclische proteinkinaseinhibitoren |
| CN1968706A (zh) | 2004-06-03 | 2007-05-23 | 霍夫曼-拉罗奇有限公司 | 用顺铂和egfr－抑制剂治疗 |
| KR20070034512A (ko) * | 2004-06-18 | 2007-03-28 | 암브룩스, 인코포레이티드 | 신규 항원-결합 폴리펩티드 및 이의 용도 |
| MX2007008768A (es) | 2005-01-21 | 2007-10-19 | Genentech Inc | Dosificacion fija de anticuerpos her. |
| JP5328155B2 (ja) * | 2005-02-02 | 2013-10-30 | マクロジェニックス ウエスト， インコーポレイテッド | Ａｄａｍ−９モジュレータ |
| CN103251946A (zh) | 2005-02-23 | 2013-08-21 | 健泰科生物技术公司 | 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活 |
| US20090215992A1 (en) * | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
| DK1937244T3 (en) | 2005-09-30 | 2018-10-29 | Io Therapeutics Llc | : CANCER TREATMENT WITH SPECIFIC RXR AGONISTS |
| KR20080077238A (ko) * | 2005-12-01 | 2008-08-21 | 도만티스 리미티드 | 인터루킨 1 수용체 타입 1에 결합하는 비경쟁적 도메인항체 포맷 |
| US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
| ES2702128T3 (es) * | 2006-05-16 | 2019-02-27 | Io Therapeutics Llc | Antagonista o agonista inverso de RAR para uso en el tratamiento de efectos secundarios de quimioterapia y/o terapia de radiación |
| CU23612A1 (es) * | 2006-09-29 | 2010-12-08 | Centro Inmunologia Molecular | Combinaciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico |
| WO2008091701A2 (en) | 2007-01-25 | 2008-07-31 | Dana-Farber Cancer Institute | Use of anti-egfr antibodies in treatment of egfr mutant mediated disease |
| PE20090681A1 (es) | 2007-03-02 | 2009-06-10 | Genentech Inc | Prediccion de respuesta a un inhibidor her |
| CA2680854C (en) | 2007-03-15 | 2017-02-14 | Ludwig Institute For Cancer Research | Treatment method using egfr antibodies and src inhibitors and related formulations |
| US20100203043A1 (en) * | 2007-04-13 | 2010-08-12 | Ree Anne H | Treatment and diagnosis of metastatic prostate cancer with inhibitors of epidermal growth factor receptor (egfr) |
| BRPI0812398A2 (pt) * | 2007-06-06 | 2019-09-24 | Domantis Ltd | domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| ES2417148T3 (es) | 2007-06-08 | 2013-08-06 | Genentech, Inc. | Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2 |
| MX2010001757A (es) | 2007-08-14 | 2010-09-14 | Ludwig Inst Cancer Res | Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo. |
| JP2011510018A (ja) * | 2008-01-18 | 2011-03-31 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 癌治療のためのイミダゾピラジノール誘導体 |
| EP2283020B8 (en) * | 2008-05-19 | 2012-12-12 | OSI Pharmaceuticals, LLC | Substituted imidazopyr-and imidazotri-azines |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| EP2408479A1 (en) | 2009-03-18 | 2012-01-25 | OSI Pharmaceuticals, LLC | Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor |
| CN102356092B (zh) | 2009-03-20 | 2014-11-05 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
| EP2421837A1 (en) | 2009-04-20 | 2012-02-29 | OSI Pharmaceuticals, LLC | Preparation of c-pyrazine-methylamines |
| JP2012526138A (ja) * | 2009-05-07 | 2012-10-25 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 副腎皮質癌を治療するためのｏｓｉ−９０６の使用 |
| SG10201507044PA (en) | 2009-05-29 | 2015-10-29 | Hoffmann La Roche | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| CA2784211C (en) | 2010-02-18 | 2019-12-24 | Genentech, Inc. | Neuregulin antagonists and use thereof in treating cancer |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| US20130245233A1 (en) | 2010-11-24 | 2013-09-19 | Ming Lei | Multispecific Molecules |
| WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
| MX2014001766A (es) | 2011-08-17 | 2014-05-01 | Genentech Inc | Anticuerpos de neuregulina y sus usos. |
| US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
| SG11201402510TA (en) | 2011-11-30 | 2014-06-27 | Genentech Inc | Erbb3 mutations in cancer |
| WO2013083810A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
| US10653650B2 (en) | 2011-12-13 | 2020-05-19 | Io Therapeutics, Inc. | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists |
| CN104114171A (zh) | 2011-12-13 | 2014-10-22 | Io治疗公司 | 使用rxr激动剂的自身免疫紊乱的治疗 |
| JP2015514710A (ja) | 2012-03-27 | 2015-05-21 | ジェネンテック， インコーポレイテッド | Ｈｅｒ３阻害剤に関する診断及び治療 |
| BR112015012644A2 (pt) | 2012-11-30 | 2017-12-19 | Hoffmann La Roche | método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit; |
| MX364892B (es) | 2015-10-31 | 2019-05-10 | Io Therapeutics Inc | Tratamiento de trastornos del sistema nervioso utilizando combinaciones de agonistas de rxr y hormonas tiroideas. |
| EP3426302B1 (en) | 2016-03-10 | 2022-12-14 | IO Therapeutics, Inc. | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones |
| DK3426303T3 (da) | 2016-03-10 | 2022-09-19 | Io Therapeutics Inc | Behandling af muskellidelser med kombinationer af rxr-agonister og thyroideahormoner |
| US20190151346A1 (en) | 2016-05-10 | 2019-05-23 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
| EP3684348A4 (en) | 2017-09-20 | 2021-08-18 | IO Therapeutics, Inc. | TREATMENT OF DISEASE WITH SELECTIVE RXR AGONIST ESTERS |
| US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
| CN113207799B (zh) * | 2021-03-19 | 2022-03-15 | 中山大学 | 一种二型糖尿病小鼠快速心衰模型的构建方法 |
| WO2023108015A1 (en) | 2021-12-07 | 2023-06-15 | Io Therapeutics, Inc. | Use of an rxr agonist in treating drug resistant her2+ cancers |
| JP2024543621A (ja) | 2021-12-07 | 2024-11-21 | アイオー セラピューティクス インコーポレイテッド | Ｈｅｒ２＋がんの治療におけるｒｘｒアゴニストおよびタキサンの使用 |
| CN116333117B (zh) * | 2021-12-16 | 2024-04-26 | 徕特康(苏州)生物制药有限公司 | 抗表皮生长因子受体抗体及其制备方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0531472T3 (da) * | 1991-03-06 | 2003-12-01 | Merck Patent Gmbh | Humaniserede monoklonale antistoffer |
| ES2163293T5 (es) * | 1997-08-15 | 2006-01-16 | Cephalon, Inc. | Combinacion de un inhibidor de tirosina quinasas y castracion quimica para tratar el cancer de prostata. |
| WO1999059636A1 (en) * | 1998-05-20 | 1999-11-25 | Kyowa Hakko Kogyo Co., Ltd. | Vegf activity inhibitors |
| KR20020000223A (ko) * | 1999-05-14 | 2002-01-05 | 존 비. 랜디스 | 표피성장인자 수용체 길항제를 사용한 인간 난치성 종양의치료 방법 |
| EP2111870A1 (en) * | 1999-08-27 | 2009-10-28 | Genentech, Inc. | Dosages for treatment of anti-erbB2 antibodies |
| EP1343820A4 (en) * | 2000-10-13 | 2005-09-14 | Uab Research Foundation | HUMANE SINGLE CHAIN ANTI EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY |
-
2002
- 2002-04-22 BR BR0209147-0A patent/BR0209147A/pt not_active IP Right Cessation
- 2002-04-22 SK SK1463-2003A patent/SK14632003A3/sk not_active Application Discontinuation
- 2002-04-22 CA CA002449166A patent/CA2449166A1/en not_active Abandoned
- 2002-04-22 HU HU0303976A patent/HUP0303976A3/hu unknown
- 2002-04-22 PL PL02363322A patent/PL363322A1/xx unknown
- 2002-04-22 KR KR10-2003-7014552A patent/KR20040029975A/ko not_active Withdrawn
- 2002-04-22 WO PCT/EP2002/004404 patent/WO2002089842A1/en not_active Ceased
- 2002-04-22 AU AU2002315306A patent/AU2002315306B2/en not_active Ceased
- 2002-04-22 EP EP02740492A patent/EP1385546A1/en not_active Withdrawn
- 2002-04-22 MX MXPA03010121A patent/MXPA03010121A/es unknown
- 2002-04-22 CN CNA028095146A patent/CN1507355A/zh active Pending
- 2002-04-22 JP JP2002586974A patent/JP2004528368A/ja not_active Withdrawn
- 2002-04-22 CZ CZ20033226A patent/CZ20033226A3/cs unknown
- 2002-04-22 RU RU2003134180/15A patent/RU2003134180A/ru not_active Application Discontinuation
- 2002-04-22 US US10/476,478 patent/US20040131611A1/en not_active Abandoned
-
2003
- 2003-12-04 ZA ZA200309437A patent/ZA200309437B/en unknown
-
2007
- 2007-04-26 US US11/789,883 patent/US20070202101A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2416399C2 (ru) * | 2005-06-29 | 2011-04-20 | Хилл'С Пет Ньютришн, Инк. | Способы и композиции для профилактики и лечения воспалительного заболевания |
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03010121A (es) | 2004-03-10 |
| HUP0303976A3 (en) | 2006-11-28 |
| KR20040029975A (ko) | 2004-04-08 |
| PL363322A1 (en) | 2004-11-15 |
| BR0209147A (pt) | 2004-06-08 |
| HUP0303976A2 (hu) | 2004-03-01 |
| EP1385546A1 (en) | 2004-02-04 |
| CZ20033226A3 (en) | 2004-07-14 |
| US20070202101A1 (en) | 2007-08-30 |
| JP2004528368A (ja) | 2004-09-16 |
| US20040131611A1 (en) | 2004-07-08 |
| SK14632003A3 (sk) | 2004-03-02 |
| CN1507355A (zh) | 2004-06-23 |
| CA2449166A1 (en) | 2002-11-14 |
| WO2002089842A1 (en) | 2002-11-14 |
| AU2002315306B2 (en) | 2007-05-17 |
| ZA200309437B (en) | 2005-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003134180A (ru) | Комбинированная терапия, использующая антитела к egfr и антигормональные средства | |
| KR101088661B1 (ko) | Ｅｒｂ－ｂ１ 수용체를 표적으로 하는 약학적 조성물 | |
| CA2436326C (en) | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors | |
| CN102812045B (zh) | 用于治疗或预防人表皮生长因子受体‑3(her‑3)相关疾病的材料和方法 | |
| EP0616812B1 (en) | Combination with anti-hormonal compounds and binding molecules for the treatment of cancer | |
| US9522956B2 (en) | Combination therapy using anti-EGFR and anti-HER2 antibodies | |
| EA200101064A1 (ru) | Лечение раковых заболеваний путем комбинированного введения доцетаксела с рекомбинантными гуманизированными моноклональными анти-her2 антителами | |
| AU2002219221A1 (en) | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors | |
| JP2005533001A5 (ru) | ||
| WO2001087334A1 (en) | Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents | |
| KR20200018785A (ko) | 유방암 치료를 위한 ErbB-2/ErbB-3 이중특이적 항체와 내분비 치료의 조합 | |
| CN1946740B (zh) | 抗人腱生蛋白单克隆抗体 | |
| KR101637689B1 (ko) | 아토르바스타틴을 유효성분으로 포함하는 항체의 종양 침투력 증진용 조성물 및 이의 용도 | |
| CN100408097C (zh) | 双特异性抗erb-b抗体及其在肿瘤治疗中的用途 | |
| EP4005593A1 (en) | Multivariable dosing method for use in treating high-egfr expression cancer | |
| HK1081448B (en) | Bispecific anti-erb-b antibodies and their use in tumor therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20060801 |